Edotreotide acetate lyophilized kits
| DOTA-Tyr3-Octreotide (Edotreotide acetate) | 0.072-0.088 mg |
| Gentisic acid | 14.4-17.6 mg |
| Non-toxic Inositol | 36.0-44.0 mg |
| Non-toxic Ascorbic Acid | 64.0-78.2 mg |
|
A cold GMP kit, pharmaceutical grade and ready to be labeled with 90Y,
according to a defined labeling protocol, for the treatment of metastatic
carcinoid and pancreatic neuroendocrine tumors in patients whose symptoms
are not controlled by conventional therapy.
For more information please contact info@biomedica.gr.
Octreotide Acetate
DOTA-(Tyr3)-Octreotide Acetate
C65H92N14O18S2
|
|
DOTA-Conjugated somatostatin analog for labeling with radiometals
like 68Ga,111In,90Y and 177Lu. Potentially useful for receptor-
mediated tumor imaging.
For more information please contact info@biomedica.gr.
|
|
|
Biomedica Life Sciences S.A. is a privately held, vertically integrated Specialty Pharmaceutical Company,
headquartered in Greece (Athens), focused on the emerging field of Nuclear Medicine and more specifically
in the Molecular Imaging and Targeted Therapies. The Company since its establishment in 1987 is dynamically
active in the Health Sector and has established a leading position in covering the market needs of the health
industry in diagnostic and therapeutic products, specific medical devices and services. Biomedica Life
Sciences S.A. has launched and marketed a unique portfolio of innovative radiopharmaceutical products in Greece.
The Company’s core activity, utilizing the expertise that has been developed through the past years, spans over the following fields:
 |
Development and commercialization of innovative radiopharmaceutical products and services through internal R&D efforts
|
|
Sourcing late stage radiopharmaceutical diagnostics and therapies for development and commercialization in Europe, Turkey and the Middle East
|
|
Investing in research partnerships with academic institutions and research centers
|
|
|
|
Biomedica Life Sciences S.A. in order to optimize its efficiency in exploiting the results of the R&D activities,
has established two Spin-off Companies in which is the controlling shareholder.
The companies are :
|
|
| |
Biomedica Life Sciences S.A
2 Tenedou Street, Vrilissia
15235 Athens, Greece
|
|
|
